Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-12-04T09:19:24.247Z Has data issue: false hasContentIssue false
  • English
  • Français

Biperiden and Piroheptine Do Not Affect the Serum Level of Zotepine, a New Antipsychotic Drug

Published online by Cambridge University Press:  02 January 2018

K. Otani ,
T. Hirano ,
T. Kondo ,
S. Kaneko ,
Y. Fukushima ,
K. Noda  and
Y. Tashiro
K. Otani*
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
T. Hirano
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
T. Kondo
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
S. Kaneko
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
Y. Fukushima
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
K. Noda
Affiliation:
Department of Neuropsychiatry, Hirosaki University Hospital, Japan
Y. Tashiro
Affiliation:
The Research Laboratories, Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan
*
∗Department of Neuropsychiatry, Hirosaki University Hospital, Hirosaki, Japan
Get access Rights & Permissions [Opens in a new window]

Abstract

The effects of biperiden and piroheptine on the serum level of zotepine were studied in 15 schizophrenic and 6 mentally retarded in-patients. Neither of these anticholinergic drugs affected the serum level of zotepine nor caused significant side-effects. In the schizophrenics the total scores on the BPRS did not change significantly with either combination of drugs.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 157 , Issue 1 , July 1990 , pp. 128 - 130
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bamrah, J. S., Kumar, V., Krska, J., et al (1986) Interactions between procyclidine and neuroleptic drugs: some pharmacological and clinical aspects. British Journal of Psychiatry, 149, 726–733.Google Scholar
Bolvig Hansen, L., Elley, J., Rosted Christensen, T., et al (1979) Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. British Journal of Clinical Pharmacology, 7, 75–80.Google Scholar
Fisch, R. Z. (1987) Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia. Acta Psychiatrica Scandinavica, 75, 91–94.Google Scholar
Hitomi, M., Kumadaki, N., Fukuhara, T., et al (1972a) Pharmacological study of piroheptine, a new antiparkinson drug, 3-(10,11-dihydro-5h-dibenzo [a, d] cyclohepten-5-ylidene)-1-ethyl-2-methylpyrrolidine. I. Effects on drug-induced tremor and catatonia, and on adrenergic actions. Arzneimittel-Forschung, 22, 953–961.Google Scholar
Hitomi, M., Watanabe, N., Kumadaki, N., et al (1972b) Pharmacological study of piroheptine, a new antiparkinson drug. II. Anticholinergic, antihistaminic, and psychopharmacological actions and toxicity. Arzneimittel-Forschung, 22, 961–966.Google Scholar
Imai, H., Nakamura, M., Fukui, Y., et al (1980) Comparison of efficacy of zotepine and perphenazine in schizophrenia by double-blind, controlled study (in Japanese). Japanese Journal of Neuropsychopharmacology, 2, 285–299.Google Scholar
Ishikawa, H. (1972) Clinical experience with FK-1190 for drug-induced parkinsonisms (in Japanese). Pharmacotherapy, 5, 1763–1775.Google Scholar
Johnstone, E. C., Crow, T. J., Ferrier, N., et al (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine, 13, 513–527.Google Scholar
Lingjarde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 76 (suppl. 334).Google Scholar
Linnoila, M., Viukari, M., Vaisanen, K., et al (1980) Effect of anticonvulsants on plasma haloperidol and thioridazine levels. American Journal of Psychiatry, 137, 819–821.Google Scholar
Loga, S., Curry, S. & Lader, M. (1975) Interaction of orphenadrine and phenobarbitone with chlorpromazine. Plasma concentrations and effects in man. British Journal of Clinical Pharmacology, 2, 197–208.Google Scholar
Noda, K., Suzuki, A., Okui, M., et al (1979) Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo[b,f]thiepine (Zotepine) in rat, mouse, dog and man. Arzneimittel-Forschung, 29, 1595–1600.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Rivera-Galimlim, L. (1982) Problems in therapeutic blood monitoring of chlorpromazine. Therapeutic Drug Monitoring, 4, 41–49.Google Scholar
Singh, M. M. & Kay, S. R. (1979) Therapeutic antagonism between anticholinergic antiparkinsonism agents and neuroleptic in schizophrenia. Implication for a neuropharmacological model. Neuropsychobiology, 5, 74–86.Google Scholar
Uchida, S., Honda, F., Otsuka, M., et al (1979) Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy)-dibenzo-[b,f] thiepine] (Zotepine), a new neuroleptic drug. Arzneimittel-Forschung, 29, 1588–1594.Google Scholar
von Bardeleben, U., Benkert, O. & Holsboer, F. (1987) Clinical and neuroendocrine effects of zotepine – a new neuroleptic drug. Pharmacopsychiatry, 20, 28–34.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.